½ÃÀ庸°í¼­
»óǰÄÚµå
1548169

¼¼°è »öÀü ¿ä¹ý ½ÃÀå Á¶»ç º¸°í¼­ : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ ¿¹Ãø(2024-2032³â)

Global Embolotherapy Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Value Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 181 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

»öÀü ¿ä¹ý ½ÃÀåÀÇ ¼¼°è ¼ö¿ä´Â 2023³â 48¾ï 7,000¸¸ ´Þ·¯¿¡¼­ 2032³â¿¡´Â ¾à 106¾ï 8,000¸¸ ´Þ·¯ ½ÃÀå ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ÃßÁ¤µÇ¸ç, Á¶»ç ±â°£ 2024-2032³âÀÇ CAGRÀº 9.12%·Î ÃßÁ¤µË´Ï´Ù.

»öÀü ¿ä¹ýÀº »öÀüÁ¦¸¦ µµÀÔÇÏ¿© Ç÷°üÀ» Æó»öÇϰí Ç÷°ü »óŸ¦ Ä¡·áÇÏ´Â µ¥ »ç¿ëµÇ´Â ÀÇ·á ±â¼úÀÔ´Ï´Ù. ÀÌ ³·Àº ħ½ÀÀû ÀýÂ÷´Â ÄÚÀÏ, ÀÔÀÚ ¶Ç´Â ¾×ü ¾à¹°À» Ç÷°ü¿¡ ÁÖÀÔÇÏ¿© Ç¥Àû ºÎÀ§·ÎÀÇ Ç÷·ù¸¦ Â÷´ÜÇϰųª °¨¼Ò½Ãŵ´Ï´Ù. Àڱà ±ÙÁ¾, ƯÁ¤ Á¾¾ç, µ¿Á¤¸Æ ±âÇü µîÀÇ »óŸ¦ °ü¸®ÇÕ´Ï´Ù. ÀÌ ÀÇ·á ±â¼úÀº Ç÷¾× °ø±ÞÀ» ¼±ÅÃÀûÀ¸·Î Â÷´ÜÇÏ¿© ºñÁ¤»óÀûÀÎ Áõ½ÄÀ» ÁÙÀ̰ųª Á¦°ÅÇϰí ÃâÇ÷À» ÁÙÀ̰í Áõ»óÀ» ¿ÏÈ­ÇÏ´Â °ÍÀ» ¸ñÇ¥·ÎÇÕ´Ï´Ù. ÀÌ ÀýÂ÷´Â »öÀü ¹°ÁúÀ» Á¤È®ÇÏ°Ô Àü´ÞÇϱâ À§ÇØ À̹ÌÁö À¯µµ¸¦ »ç¿ëÇÕ´Ï´Ù. ±âÁ¸ÀÇ ¼ö¼úº¸´Ù ³·Àº ħ½ÀÀ¸·Î ȸº¹ ½Ã°£ ´ÜÃà°ú ÇÕº´ÁõÀÇ À§ÇèÀ» ÁÙÀÌ´Â µîÀÇ ÀÌÁ¡ÀÌ ÀÖÀ¸¸ç, Çö´ëÀÇ ÁßÀç ¹æ»ç¼±Çп¡¼­ ±ÍÁßÇÑ ÀÚ»êÀÌ µÇ°í ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ

»öÀü ¿ä¹ý ½ÃÀåÀº Àڱà ±ÙÁ¾, µ¿Á¤¸Æ ±âÇü(AVM), ƯÁ¤ Á¾¾ç µî »öÀü ¿ä¹ýÀÌ ÀûÀÀÇÏ´Â Áúº´ÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó È®´ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áúº´ÀÇ ÀÌȯÀ² Áõ°¡¿Í È¿°úÀûÀÎ Ä¡·á ¿É¼ÇÀ¸·Î »öÀü ¿ä¹ýÀÇ ÀÎÁöµµ Áõ°¡°¡ ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ±â¼úÀû Áøº¸´Â ½ÃÀå¿¡ Å« ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. º¸´Ù È¿°úÀûÀÌ°í »ýüÀûÇÕ¼ºÀÌ ³ôÀº Àç·áÀÇ °³¹ßÀ» Æ÷ÇÔÇÑ »öÀüÁ¦ÀÇ ±â¼ú Çõ½ÅÀº Ä¡·á ¼ºÀûÀ» Çâ»ó½ÃŰ°í »öÀü ¿ä¹ýÀ¸·Î ´ëóÇÒ ¼ö ÀÖ´Â ÁúȯÀÇ ¹üÀ§¸¦ È®´ëÇÕ´Ï´Ù. ½Ç½Ã°£ Åõ½Ã ¹× 3D À̹ÌÁö¿Í °°Àº °í±Þ À̹ÌÁö ±â¼úÀº »öÀü ¿ä¹ýÀÇ Á¤È®¼º°ú ¾ÈÀü¼ºÀ» ´õ¿í Çâ»ó½Ã۰í äÅÃÀ» µÞ¹ÞħÇÕ´Ï´Ù.

³·Àº ħ½À Ä¡·á¿¡ ´ëÇÑ µ¿Çâµµ ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÕ´Ï´Ù. »öÀü ¿ä¹ýÀº ±âÁ¸ÀÇ ¼ö¼ú Á¢±Ù¹ý¿¡ ºñÇØ ħ½À¼ºÀÌ ³·¾Æ ȸº¹ ½Ã°£ ´ÜÃà°ú ÇÕº´Áõ ¹ß»ý·ü ÀúÇÏ·Î À̾îÁý´Ï´Ù. ȯÀÚÀÇ ¼±È£µµ°¡ ³·Àº ħ½ÀÀûÀÎ ¼±ÅÃÀ¸·Î À̵¿ÇÔ¿¡ µû¶ó »öÀü ¿ä¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. °Ô´Ù°¡, ½ÅÈï ½ÃÀå¿¡¼­ÀÇ °Ç°­ °ü¸® Á¢±ÙÀÇ È®´ë´Â ¼ºÀå ±âȸ¸¦ °¡Á®¿É´Ï´Ù. ÀÌ Áö¿ª¿¡¼­´Â °Ç°­ °ü¸® ÀÎÇÁ¶ó°¡ °³¼±µÇ°í ÁßÀç ¹æ»ç¼±ÇÐ ±â¼úÀÇ ÀÎÁöµµ°¡ ³ô¾ÆÁü¿¡ µû¶ó °í±Þ Ä¡·á¿¡ ´ëÇÑ Á¢±Ù¼º Çâ»ó°ú ÀÇ·á ÅõÀÚ Áõ°¡·Î »öÀü ¿ä¹ýÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±×·¯³ª ³ôÀº ºñ¿ë°ú ÀáÀçÀûÀÎ ÀýÂ÷ À§ÇèÀº ½ÃÀå ¼ºÀåÀ» ¾ïÁ¦ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Á¶»ç º¸°í¼­´Â Porter's Five Force ¸ðµ¨, ½ÃÀå ¸Å·Â ºÐ¼® ¹× ¹ë·ùüÀÎ ºÐ¼®À» ´Ù·ì´Ï´Ù. ÀÌ·¯ÇÑ µµ±¸´Â ¾÷°èÀÇ ±¸Á¶¸¦ ¸íÈ®ÇÏ°Ô ÆÄ¾ÇÇÏ°í ¼¼°è ¼öÁØÀÇ °æÀïÀÇ ¸Å·ÂÀ» Æò°¡ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ, ÀÌ·¯ÇÑ µµ±¸´Â »öÀü ¿ä¹ý ¼¼°è ½ÃÀå¿¡¼­ °¢ ºÎ¹®À» Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. »öÀü ¿ä¹ý »ê¾÷ÀÇ ¼ºÀå°ú µ¿ÇâÀºÀÌ ¿¬±¸¿¡ Àü¹ÝÀûÀÎ Á¢±ÙÀ» Á¦°øÇÕ´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­

ÀÌ ¼½¼Ç¿¡¼­´Â »öÀü ¿ä¹ý ½ÃÀå º¸°í¼­ÀÇ ±¹°¡º° ¹× Áö¿ªº° ºÎ¹®¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ µ¥ÀÌÅ͸¦ Á¦°øÇÔÀ¸·Î½á Àü·«°¡°¡ °¢ Á¦Ç° ¶Ç´Â ¼­ºñ½ºÀÇ Å¸°Ù °èÃþÀ» ÆÄ¾ÇÇϰí ÇâÈÄ ºñÁî´Ï½º ±âȸ¿¡ µµ¿òÀ» ÁÙ ¼ö ÀÖ½À´Ï´Ù.

Á¦Ç°º°

  • »öÀüÁ¦
  • ¹Ì¼Ò±¸
  • »öÀü ÄÚÀÏ(µðÅ×ÀÌÃĺí ÄÚÀÏ, Ǫ¼Åºí ÄÚÀÏ)
  • ¾×ü »öÀüÁ¦
  • »öÀü Ç÷¯±× ½Ã½ºÅÛ
  • dz¼±
  • Áö¿ø ÀåÄ¡
  • ¸¶ÀÌÅ©·ÎÄ«Å×ÅÍ
  • °¡À̵å¿ÍÀ̾î

ÀûÀÀ Áúȯº°

  • ¾Ï
  • °£¾Ï
  • ½ÅÀå¾Ï
  • ±âŸ ¾Ï
  • ¸»ÃÊ Ç÷°ü Áúȯ
  • ½Å°æÁúȯ
  • ³úµ¿¸Æ·ù
  • ³úµ¿Á¤¸Æ ±âÇü ¹× ´©°ø
  • ¼ÒÈ­±â Áúȯ
  • ºñ´¢±â ¹× ½ÅÀå Áúȯ

ÀýÂ÷º° ºÐ¼®

  • Ä«Å×ÅÍ °æÀ¯ µ¿¸Æ »öÀü¼ú
  • Ä«Å×ÅÍ °æÀ¯ µ¿¸Æ ¹æ»ç¼± »öÀü¼ú/¼±ÅÃÀû ü³» ¹æ»ç¼± ¿ä¹ý
  • °æµ¿¸Æ È­ÇÐ »öÀü ¿ä¹ý

ÃÖÁ¾ »ç¿ëÀÚº° ºÐ¼®

  • º´¿ø ¹× Áø·á¼Ò
  • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
  • ±âŸ ÃÖÁ¾ »ç¿ëÀÚ

Áö¿ªº° ºÐ¼®

ÀÌ ¼½¼Ç¿¡¼­´Â ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«¿¡¼­ »öÀü ¿ä¹ý ½ÃÀåÀÇ ÇöÀç ¹× ¹Ì·¡ ¼ö¿ä¸¦ °­Á¶ÇÏ´Â Áö¿ª Àü¸ÁÀ» ´Ù·ì´Ï´Ù. ¶ÇÇÑ, Àú¸íÇÑ ¸ðµç Áö¿ª¿¡¼­ÀÇ °³º° ¿ëµµ ºÎ¹® ¼ö¿ä¡¤ÃßÁ¤¡¤¿¹Ãø¿¡µµ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù.

¸ÂÃ㠿䱸»çÇ×ÀÌ ÀÖ´Â °æ¿ì ´ç»ç¿¡ ¹®ÀÇÇϼ¼¿ä. ´ç»çÀÇ ¼³¹®Á¶»çÆÀÀº °í°´ÀÇ ¿ä±¸¿¡ µû¶ó ¸ÂÃãÇü º¸°í¼­¸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ½ÃÀåÀÇ ÇÏÀ̶óÀÌÆ®
  • ¼¼°è ½ÃÀå ÇöȲ

Á¦3Àå »öÀü ¿ä¹ý- »ê¾÷ ºÐ¼®

  • ¼Ò°³ - ½ÃÀå ¿ªÇÐ
  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ±âȸ
  • ¾÷°è µ¿Çâ
  • Porter's Five Forces ºÐ¼®
  • ½ÃÀåÀÇ ¸Å·Â ºÐ¼®

Á¦4Àå ¹ë·ùüÀÎ ºÐ¼®

  • ¹ë·ùüÀÎ ºÐ¼®
  • ¿øÀç·á ºÐ¼®
    • ¿øÀç·á ¸®½ºÆ®
    • ¿øÀç·á Á¦Á¶¾÷ü ¸®½ºÆ®
    • ÁÖ¿ä ¿øÀç·áÀÇ °¡°Ý µ¿Çâ
  • ÀáÀçÀû ±¸¸ÅÀÚ ¸ñ·Ï
  • ¸¶ÄÉÆÃ Ã¤³Î
    • Á÷Á¢ ¸¶ÄÉÆÃ
    • °£Á¢ ¸¶ÄÉÆÃ
    • ¸¶ÄÉÆÃ Ã¤³Î ¹ßÀü µ¿Çâ

Á¦5Àå »öÀü ¿ä¹ý ¼¼°è ½ÃÀå ºÐ¼® : Á¦Ç°º°

  • Á¦Ç°º° °³¿ä
  • Á¦Ç°º° °ú°Å ¹× ¿¹Ãø µ¥ÀÌÅÍ ºÐ¼®
  • »öÀüÁ¦
  • ¹Ì¼Ò±¸
  • »öÀü¿ë ÄÚÀÏ(Å»Âø½Ä ÄÚÀÏ, Ǫ¼Åºí ÄÚÀÏ)
  • ¾×ü »öÀüÁ¦
  • »öÀü Ç÷¯±× ½Ã½ºÅÛ
  • dz¼±
  • Áö¿ø ÀåÄ¡
  • ¸¶ÀÌÅ©·ÎÄ«Å×ÅÍ
  • °¡À̵å¿ÍÀ̾î

Á¦6Àå »öÀü ¿ä¹ý ¼¼°è ½ÃÀå ºÐ¼® : ÀûÀÀ Áúȯº°

  • ÀûÀÀ Áúȯº° °³¿ä
  • ÀûÀÀ Áúȯº° °ú°Å ¹× ¿¹Ãø µ¥ÀÌÅÍ ºÐ¼®
  • ¾Ï
  • °£¾Ï
  • ½ÅÀå¾Ï
  • ±âŸ ¾Ï
  • ¸»ÃÊ Ç÷°ü Áúȯ
  • ½Å°æÁúȯ
  • ³úµ¿¸Æ·ù
  • ³úµ¿Á¤¸Æ ±âÇü ¹× ´©°ø
  • ¼ÒÈ­±â Áúȯ
  • ºñ´¢±â ¹× ½ÅÀå Áúȯ

Á¦7Àå ¼¼°èÀÇ »öÀü¿ä¹ý ½ÃÀå ºÐ¼® : ¼ö±âº° ºÐ¼®

  • °³¿ä ¼ö±âº° ºÐ¼®
  • °ú°Å ¹× ¿¹Ãø µ¥ÀÌÅÍ ºÐ¼® ÀýÂ÷º° ºÐ¼®
  • Ä«Å×ÅÍ °æÀ¯ µ¿¸Æ »öÀü¼ú
  • Ä«Å×ÅÍ °æÀ¯ µ¿¸Æ ¹æ»ç¼± »öÀü ¿ä¹ý/¼±ÅÃÀû ³»ºÎ ¹æ»ç¼± ¿ä¹ý
  • °æµ¿¸Æ È­ÇÐ »öÀü ¿ä¹ý

Á¦8Àå »öÀü ¿ä¹ý ¼¼°è ½ÃÀå ºÐ¼® : ÃÖÁ¾ »ç¿ëÀÚº° ºÐ¼®

  • ÃÖÁ¾ »ç¿ëÀÚº° ºÐ¼® °³¿ä
  • °ú°Å ¹× ¿¹Ãø µ¥ÀÌÅÍ ºÐ¼® ÃÖÁ¾ »ç¿ëÀÚº° ºÐ¼®
  • º´¿ø ¹× Áø·á¼Ò
  • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
  • ±âŸ ÃÖÁ¾ »ç¿ëÀÚ

Á¦9Àå »öÀü ¿ä¹ý ¼¼°è ½ÃÀå ºÐ¼® : Áö¿ªº°

  • Áö¿ªº° Àü¸Á
  • ¼Ò°³
  • ºÏ¹Ì ¸ÅÃ⠺м®
    • °³¿ä, ºÐ¼®°ú ¿¹Ãø
    • ºÏ¹Ì : ºÎ¹®º°
    • ºÏ¹Ìº°
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´ ¸ÅÃ⠺м®
    • °³¿ä, ºÐ¼®°ú ¿¹Ãø
    • À¯·´ ºÎ¹®º°
    • À¯·´ ±¹°¡º°
    • ¿µ±¹
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • ÀÌÅ»¸®¾Æ
    • ·¯½Ã¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç ¸ÅÃ⠺м®
    • °³¿ä, ºÐ¼®°ú ¿¹Ãø
    • ¾Æ½Ã¾ÆÅÂÆò¾ç ºÎ¹®º°
    • ¾Æ½Ã¾ÆÅÂÆò¾ç ±¹°¡º°
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • È£ÁÖ
    • µ¿³²¾Æ½Ã¾Æ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä« ¸ÅÃ⠺м®
    • °³¿ä, ºÐ¼®°ú ¿¹Ãø
    • ¶óƾ¾Æ¸Þ¸®Ä« ºÎ¹®º°
    • ¶óƾ¾Æ¸Þ¸®Ä« ±¹°¡º°
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • Æä·ç
    • Ä¥·¹
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ¸ÅÃ⠺м®
    • °³¿ä, ºÐ¼®°ú ¿¹Ãø
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ºÎ¹®º°
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ±¹°¡º° À϶÷
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • À̽º¶ó¿¤
    • ³²¾ÆÇÁ¸®Ä«
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦10Àå »öÀü ¿ä¹ý ±â¾÷°æÀï ±¸µµ

  • »öÀü ¿ä¹ý ½ÃÀåÀÇ °æÀï
  • Á¦ÈÞ, Çù·Â, ÇÕÀÇ
  • ÇÕº´ ¹× Àμö
  • ½ÅÁ¦Ç° ¹ß¸Å
  • ±âŸ °³¹ß

Á¦11Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • ÁÖ¿ä ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®
  • ½ÃÀå ÁýÁßµµ
  • Merit Medical Systems
  • Boston Scientific Corporation
  • Medtronic Plc
  • Meril Life Sciences Pvt. Ltd
JHS 24.10.02

The global demand for Embolotherapy Market is presumed to reach the market size of nearly USD 10.68 Billion by 2032 from USD 4.87 Billion in 2023 with a CAGR of 9.12% under the study period 2024-2032.

Embolotherapy is a medical technique used to occlude blood vessels and treat vascular conditions by introducing embolic agents. This minimally invasive procedure involves injecting coils, particles, or liquid agents into blood vessels to block or reduce blood flow to targeted areas. It manages conditions like uterine fibroids, certain types of tumors, and arteriovenous malformations. This medical technique aims to shrink or eliminate abnormal growths, reduce bleeding, and alleviate symptoms by selectively blocking the blood supply. This technique uses imaging guidance to ensure precise delivery of the embolic material. It provides a less invasive option than traditional surgery, offering advantages like shorter recovery time and a lower risk of complications, making it a valuable asset in contemporary interventional radiology.

MARKET DYNAMICS

The embolotherapy market is expanding due to the increasing prevalence of conditions amenable to embolotherapy, such as uterine fibroids, arteriovenous malformations (AVMs), and certain tumors. The rising incidence of these conditions and the growing awareness of embolotherapy as an effective treatment option fuel market growth. Technological advancements provide substantial opportunities for the market. Innovations in embolic agents, including developing more effective and biocompatible materials, enhance treatment outcomes and expand the range of conditions that can be addressed through embolotherapy. Advanced imaging technologies, such as real-time fluoroscopy and 3D imaging, further improve the precision and safety of embolotherapy procedures, driving adoption.

The trend towards minimally invasive treatments is also contributing to market growth. Embolotherapy offers a less invasive alternative to traditional surgical approaches, leading to reduced recovery times and lower complication rates. As patient preference shifts towards minimally invasive options, the demand for embolotherapy procedures is expected to rise. Additionally, expanding healthcare access in emerging markets presents growth opportunities. As healthcare infrastructure improves and awareness of interventional radiology techniques increases in these regions, adopting embolo therapy is likely to grow, driven by enhanced access to advanced treatments and increasing healthcare investment. However, high costs and potential procedural risks can restrain market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Embolotherapy. The growth and trends of Embolotherapy industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Embolotherapy market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

  • Embolic agents
  • Microspheres
  • Embolic coils (Detachable Coils, Pushable Coils)
  • Liquid Embolic Agents
  • Embolic Plug Systems
  • Detachable Balloons
  • Support Devices
  • Microcatheters
  • Guidewires

By Disease Indication

  • Cancer
  • Liver Cancer
  • Kidney Cancer
  • Other Cancers
  • Peripheral Vascular Diseases
  • Neurological Diseases
  • Cerebral Aneurysm
  • Cerebral Arteriovenous Malformations and Fistulas
  • Gastrointestinal Disorders
  • Urological and Nephrological Disorders

By Procedure Analysis

  • Transcatheter Arterial Embolization
  • Transcatheter Arterial Radioembolization/Selective Internal Radiation Therapy
  • Transarterial Chemoembolization

By End User Analysis

  • Hospitals and Clinics
  • Ambulatory Surgical Centers
  • Other End Users

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Embolotherapy market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Embolotherapy market include Merit Medical Systems, Boston Scientific Corporation, Medtronic Plc, Meril Life Sciences Pvt. Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. EMBOLOTHERAPY - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Product
    • 3.7.2 Market Attractiveness Analysis By Disease Indication
    • 3.7.3 Market Attractiveness Analysis By Procedure Analysis
    • 3.7.4 Market Attractiveness Analysis By End User Analysis
    • 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL EMBOLOTHERAPY MARKET ANALYSIS BY PRODUCT

  • 5.1. Overview By Product
  • 5.2. Historical and Forecast Data Analysis By Product
  • 5.3. Embolic agents Historic and Forecast Sales By Regions
  • 5.4. Microspheres Historic and Forecast Sales By Regions
  • 5.5. Embolic coils (Detachable Coils, Pushable Coils) Historic and Forecast Sales By Regions
  • 5.6. Liquid Embolic Agents Historic and Forecast Sales By Regions
  • 5.7. Embolic Plug Systems Historic and Forecast Sales By Regions
  • 5.8. Detachable Balloons Historic and Forecast Sales By Regions
  • 5.9. Support Devices Historic and Forecast Sales By Regions
  • 5.10. Microcatheters Historic and Forecast Sales By Regions
  • 5.11. Guidewires Historic and Forecast Sales By Regions

6. GLOBAL EMBOLOTHERAPY MARKET ANALYSIS BY DISEASE INDICATION

  • 6.1. Overview By Disease Indication
  • 6.2. Historical and Forecast Data Analysis By Disease Indication
  • 6.3. Cancer Historic and Forecast Sales By Regions
  • 6.4. Liver Cancer Historic and Forecast Sales By Regions
  • 6.5. Kidney Cancer Historic and Forecast Sales By Regions
  • 6.6. Other Cancers Historic and Forecast Sales By Regions
  • 6.7. Peripheral Vascular Diseases Historic and Forecast Sales By Regions
  • 6.8. Neurological Diseases Historic and Forecast Sales By Regions
  • 6.9. Cerebral Aneurysm Historic and Forecast Sales By Regions
  • 6.10. Cerebral Arteriovenous Malformations and Fistulas Historic and Forecast Sales By Regions
  • 6.11. Gastrointestinal Disorders Historic and Forecast Sales By Regions
  • 6.12. Urological and Nephrological Disorders Historic and Forecast Sales By Regions

7. GLOBAL EMBOLOTHERAPY MARKET ANALYSIS BY PROCEDURE ANALYSIS

  • 7.1. Overview By Procedure Analysis
  • 7.2. Historical and Forecast Data Analysis By Procedure Analysis
  • 7.3. Transcatheter Arterial Embolization Historic and Forecast Sales By Regions
  • 7.4. Transcatheter Arterial Radioembolization/Selective Internal Radiation Therapy Historic and Forecast Sales By Regions
  • 7.5. Transarterial Chemoembolization Historic and Forecast Sales By Regions

8. GLOBAL EMBOLOTHERAPY MARKET ANALYSIS BY END USER ANALYSIS

  • 8.1. Overview By End User Analysis
  • 8.2. Historical and Forecast Data Analysis By End User Analysis
  • 8.3. Hospitals and Clinics Historic and Forecast Sales By Regions
  • 8.4. Ambulatory Surgical Centers Historic and Forecast Sales By Regions
  • 8.5. Other End Users Historic and Forecast Sales By Regions

9. GLOBAL EMBOLOTHERAPY MARKET ANALYSIS BY GEOGRAPHY

  • 9.1. Regional Outlook
  • 9.2. Introduction
  • 9.3. North America Sales Analysis
    • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.3.2 North America By Segment Sales Analysis
    • 9.3.3 North America By Country Sales Analysis
    • 9.3.4 United States Sales Analysis
    • 9.3.5 Canada Sales Analysis
    • 9.3.6 Mexico Sales Analysis
  • 9.4. Europe Sales Analysis
    • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.4.2 Europe By Segment Sales Analysis
    • 9.4.3 Europe By Country Sales Analysis
    • 9.4.4 United Kingdom Sales Analysis
    • 9.4.5 France Sales Analysis
    • 9.4.6 Germany Sales Analysis
    • 9.4.7 Italy Sales Analysis
    • 9.4.8 Russia Sales Analysis
    • 9.4.9 Rest Of Europe Sales Analysis
  • 9.5. Asia Pacific Sales Analysis
    • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.5.2 Asia Pacific By Segment Sales Analysis
    • 9.5.3 Asia Pacific By Country Sales Analysis
    • 9.5.4 China Sales Analysis
    • 9.5.5 India Sales Analysis
    • 9.5.6 Japan Sales Analysis
    • 9.5.7 South Korea Sales Analysis
    • 9.5.8 Australia Sales Analysis
    • 9.5.9 South East Asia Sales Analysis
    • 9.5.10 Rest Of Asia Pacific Sales Analysis
  • 9.6. Latin America Sales Analysis
    • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.6.2 Latin America By Segment Sales Analysis
    • 9.6.3 Latin America By Country Sales Analysis
    • 9.6.4 Brazil Sales Analysis
    • 9.6.5 Argentina Sales Analysis
    • 9.6.6 Peru Sales Analysis
    • 9.6.7 Chile Sales Analysis
    • 9.6.8 Rest of Latin America Sales Analysis
  • 9.7. Middle East & Africa Sales Analysis
    • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.7.2 Middle East & Africa By Segment Sales Analysis
    • 9.7.3 Middle East & Africa By Country Sales Analysis
    • 9.7.4 Saudi Arabia Sales Analysis
    • 9.7.5 UAE Sales Analysis
    • 9.7.6 Israel Sales Analysis
    • 9.7.7 South Africa Sales Analysis
    • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE EMBOLOTHERAPY COMPANIES

  • 10.1. Embolotherapy Market Competition
  • 10.2. Partnership/Collaboration/Agreement
  • 10.3. Merger And Acquisitions
  • 10.4. New Product Launch
  • 10.5. Other Developments

11. COMPANY PROFILES OF EMBOLOTHERAPY INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Market Concentration Rate
  • 11.3. Merit Medical Systems
    • 11.3.1 Company Overview
    • 11.3.2 Company Revenue
    • 11.3.3 Products
    • 11.3.4 Recent Developments
  • 11.4. Boston Scientific Corporation
    • 11.4.1 Company Overview
    • 11.4.2 Company Revenue
    • 11.4.3 Products
    • 11.4.4 Recent Developments
  • 11.5. Medtronic Plc
    • 11.5.1 Company Overview
    • 11.5.2 Company Revenue
    • 11.5.3 Products
    • 11.5.4 Recent Developments
  • 11.6. Meril Life Sciences Pvt. Ltd
    • 11.6.1 Company Overview
    • 11.6.2 Company Revenue
    • 11.6.3 Products
    • 11.6.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦